[…]
Vaccibody AS announces approval of amendment of IMPD allowing to start of expansion phase in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 […]
Vaccibody AS Successfully completed Private Placement of NOK 220 million (€ 24 million)
Reference is made to the press release published by Vaccibody AS (“Vaccibody” or the “Company”) on 9 December 2016 regarding […]
QUARTERLY REPORT- 2016 Q3
QUARTERLY REPORT-2016 Q2
Vaccibody announces positive results from the phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia and recommendation by the cohort review committee as well as the independent data monitoring board to continue to the expansion phase (IIa)
Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their […]
Quarterly Report – 2016 Q1
Completion of enrolment according to the study protocol for the phase I part of the VB C-01 study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre […]
Vaccibody awarded NOK 20 million (USD 2.3 million) to develop patient-specific therapeutic cancer vaccines
Therapeutic vaccine company Vaccibody today announced that it has received a grant up to NOK 20 million (USD 2.3 million) […]
Vaccibody AS announces vaccination of first patient in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter […]
